About
Himalaya Therapeutics develops conditionally active biologics (CAB antibodies) that selectively bind targets on tumor cells to provide safer and more potent cancer therapies, leveraging exclusive access to BioAtla's CAB technology in China.
Explore Himalaya Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.